Artivion AORT Cardiac tissues — Deferred preservation costs

Similar metrics at other companies

PSNLInventory And Other Deferred Costs

$6.93M+40.8%

AVBPDeferred contract costs

$69K—

KDAmortization Of Deferred Costs

$433M+5.1%

SPSCIncurred deferred costs

$21.51M-24.8%

AFLCritical care — Deferred policy acquisition costs

$1.35B+0.4%

MFICDeferred Costs, Current and Non-Current

$22.4M+0.6%

Questions, answered.

What is Artivion's cardiac tissues — deferred preservation costs?

Artivion (AORT) reported cardiac tissues — deferred preservation costs of $27.18M in Q4 2025.

How has Artivion's cardiac tissues — deferred preservation costs changed year-over-year?

Artivion's cardiac tissues — deferred preservation costs increased by 2.6% year-over-year, from $26.49M to $27.18M.

What does cardiac tissues — deferred preservation costs mean?

This metric represents the accumulated costs associated with the preservation and processing of human cardiac tissue products that have not yet been recognized as cost of goods sold. It reflects the value of inventory held in a state of readiness for surgical implantation, accounting for the specialized logistics and biological maintenance required for these medical grafts. Monitoring this balance provides insight into the company's investment in supply chain readiness and the potential future revenue realization from its tissue-based product portfolio.